Afinitor Related Published Studies
Well-designed clinical trials related to Afinitor (Everolimus)
Everolimus for subependymal giant cell astrocytoma in patients with tuberous
sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. [2014]
A randomized phase II study of everolimus for advanced pancreatic neuroendocrine
tumors in Chinese patients. [2014]
Efficacy and safety of everolimus for subependymal giant cell astrocytomas
associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised,
placebo-controlled phase 3 trial. [2013]
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer:
BOLERO-2 final progression-free survival analysis. [2013]
Everolimus for previously treated advanced gastric cancer: results of the
randomized, double-blind, phase III GRANITE-1 study. [2013]
Health-related quality of life of patients with advanced breast cancer treated
with everolimus plus exemestane versus placebo plus exemestane in the phase 3,
randomized, controlled, BOLERO-2 trial. [2013]
Efficacy and safety of everolimus for subependymal giant cell astrocytomas
associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised,
placebo-controlled phase 3 trial. [2013]
Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis
evaluating Japanese patients in the RADIANT-3 trial. [2012]
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2011.12]
Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. [2011.11]
Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. [2011.09.20]
Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. [2011.09.15]
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. [2011.08.27]
Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. [2011.08.23]
Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. [2011.07.27]
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. [2011.07]
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. [2011.06.28]
2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). [2011.06.28]
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial. [2011.06.01]
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). [2011.05.31]
Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. [2011.05]
A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. [2011.04.19]
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. [2011.04]
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). [2011.03.15]
Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). [2011.03.15]
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. [2011.03.05]
Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. [2011.03]
Everolimus for advanced pancreatic neuroendocrine tumors. [2011.02.10]
The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. [2011.02]
Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. [2011.01.13]
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. [2011.01]
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. [2011]
Management of adverse events associated with the use of everolimus in patients
with advanced renal cell carcinoma. [2011]
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup
analysis of Japanese patients from RECORD-1. [2011]
Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. [2010.12.27]
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). [2010.12.14]
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. [2010.12.01]
Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. [2010.11.01]
Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. [2010.11.01]
Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. [2010.11]
Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. [2010.11]
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. [2010.09.15]
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. [2010.09]
Everolimus in patients with autosomal dominant polycystic kidney disease. [2010.08.26]
Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis. [2010.08.15]
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2010.08.10]
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. [2010.08.01]
Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. [2010.07.15]
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. [2010.07.08]
Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease. [2010.07]
Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. [2010.06.01]
Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. [2010.06]
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. [2010.05.25]
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. [2010.05.06]
A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial. [2010.05]
Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen. [2010.05]
Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. [2010.04.27]
Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. [2010.04.15]
A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial. [2010.04]
Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. [2010.02]
Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system. [2010.02]
Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. [2010.02]
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. [2010.01.16]
3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). [2009.12]
Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. [2009.12]
Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. [2009.11.27]
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. [2009.11.01]
Everolimus de novo in liver transplantation. [2009.11]
Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). [2009.11]
Everolimus: in advanced renal cell carcinoma. [2009.10.22]
SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. [2009.10]
Role of everolimus in the treatment of renal cell carcinoma. [2009.10]
Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. [2009.08]
Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. [2009.07.27]
Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. [2009.07.15]
Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. [2009.07.15]
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. [2009.06.01]
Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. [2009.02.10]
Everolimus: in advanced renal cell carcinoma. [2009]
Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program. [2009]
Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. [2008.11]
Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. [2008.10]
Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. [2008.10]
A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. [2008.09]
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. [2008.08.09]
Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. [2008.08]
Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results. [2008.07]
Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. [2008.06]
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. [2008.04.23]
Multicenter, Randomized Study of the Use of Everolimus With Tacrolimus After Renal Transplantation Demonstrates its Effectiveness. [2008.03.27]
A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. [2008.02]
A Lower Incidence of Cytomegalovirus Infection in De Novo Heart Transplant Recipients Randomized to Everolimus. [2007.12.15]
Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation. [2007.12]
Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. [2007.06]
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. [2007.01]
Well-designed clinical trials possibly related to Afinitor (Everolimus)
New treatment strategies in advanced neuroendocrine tumours. [2011.10.07]
Coronary bifurcation lesions treated with simple approach (from the Cordoba & Las Palmas [CORPAL] Kiss Trial). [2011.05.15]
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. [2011.04.09]
Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. [2011.04.01]
Drug-eluting versus bare-metal stents in large coronary arteries. [2010.12.09]
Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). [2010.11]
|